TPO and autoimmune thrombocytopenic purpura: Thrombopoietin receptor agonists (TPO-RA), such as eltrombopag, romiplostim, and avatrombopag, have shown efficacy in treating immune thrombocytopenia; however, their efficacy in improving platelet counts due to HER2-targeted antibody-drug conjugate therapy remains unknown.